JP2021509010A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021509010A5 JP2021509010A5 JP2020530462A JP2020530462A JP2021509010A5 JP 2021509010 A5 JP2021509010 A5 JP 2021509010A5 JP 2020530462 A JP2020530462 A JP 2020530462A JP 2020530462 A JP2020530462 A JP 2020530462A JP 2021509010 A5 JP2021509010 A5 JP 2021509010A5
- Authority
- JP
- Japan
- Prior art keywords
- binder
- binding agent
- clone
- clones
- surface presentation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023174103A JP2024009895A (ja) | 2017-12-06 | 2023-10-06 | 真核細胞ディスプレイ系におけるポリペプチド薬物の開発性のための選択 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1720351.4 | 2017-12-06 | ||
| GBGB1720351.4A GB201720351D0 (en) | 2017-12-06 | 2017-12-06 | Selecting for developability in drug discovery |
| PCT/EP2018/083698 WO2019110691A1 (en) | 2017-12-06 | 2018-12-05 | Selecting for developability of polypeptide drugs in eukaryotic cell display systems |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023174103A Division JP2024009895A (ja) | 2017-12-06 | 2023-10-06 | 真核細胞ディスプレイ系におけるポリペプチド薬物の開発性のための選択 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021509010A JP2021509010A (ja) | 2021-03-18 |
| JP2021509010A5 true JP2021509010A5 (enExample) | 2022-01-06 |
| JP7744746B2 JP7744746B2 (ja) | 2025-09-26 |
Family
ID=60950392
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020530462A Active JP7744746B2 (ja) | 2017-12-06 | 2018-12-05 | 真核細胞ディスプレイ系におけるポリペプチド薬物の開発性のための選択 |
| JP2023174103A Pending JP2024009895A (ja) | 2017-12-06 | 2023-10-06 | 真核細胞ディスプレイ系におけるポリペプチド薬物の開発性のための選択 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023174103A Pending JP2024009895A (ja) | 2017-12-06 | 2023-10-06 | 真核細胞ディスプレイ系におけるポリペプチド薬物の開発性のための選択 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11499150B2 (enExample) |
| EP (1) | EP3720959A1 (enExample) |
| JP (2) | JP7744746B2 (enExample) |
| CN (1) | CN111448314B (enExample) |
| AU (1) | AU2018379426B2 (enExample) |
| CA (1) | CA3083571A1 (enExample) |
| GB (1) | GB201720351D0 (enExample) |
| WO (1) | WO2019110691A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3786292A1 (en) * | 2016-01-08 | 2021-03-03 | Maxion Therapeutics Limited | Binding members with altered diversity scaffold domains |
| GB201720162D0 (en) * | 2017-12-04 | 2018-01-17 | Univ Oxford Innovation Ltd | Method |
| WO2021018114A1 (zh) * | 2019-07-30 | 2021-02-04 | 中山康方生物医药有限公司 | 抗人p40蛋白域抗体及其用途 |
| GB202014851D0 (en) | 2020-09-21 | 2020-11-04 | Iontas Ltd | SARS-COV-2 antibodies |
| CN118525099A (zh) | 2021-08-25 | 2024-08-20 | 艾恩塔斯有限公司 | 真核细胞中表达的蛋白质变体文库的制备 |
| WO2023039528A1 (en) * | 2021-09-10 | 2023-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | Nanobody-mediated control of gene expression and epigenetic memory |
| US12091694B2 (en) | 2022-11-18 | 2024-09-17 | Seismic Therapeutic, Inc. | Fc fusion molecules and uses thereof |
| EP4646476A1 (en) | 2023-01-06 | 2025-11-12 | Seismic Therapeutic, Inc. | Protease variants and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6485943B2 (en) * | 1995-01-17 | 2002-11-26 | The University Of Chicago | Method for altering antibody light chain interactions |
| US6300065B1 (en) * | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| JP2010213725A (ja) * | 1998-01-20 | 2010-09-30 | Univ Illinois | タンパク質の酵母細胞表面ディスプレイおよびその使用 |
| US20050048578A1 (en) * | 2003-06-26 | 2005-03-03 | Epitomics, Inc. | Methods of screening for monoclonal antibodies with desirable activity |
| PT2702160T (pt) | 2011-04-27 | 2020-07-30 | Amyris Inc | Métodos para modificação genómica |
| EP2794662A1 (en) | 2011-12-22 | 2014-10-29 | F.Hoffmann-La Roche Ag | Full length antibody display system for eukaryotic cells and its use |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
-
2017
- 2017-12-06 GB GBGB1720351.4A patent/GB201720351D0/en not_active Ceased
-
2018
- 2018-12-05 CN CN201880079095.7A patent/CN111448314B/zh active Active
- 2018-12-05 US US16/767,727 patent/US11499150B2/en active Active
- 2018-12-05 WO PCT/EP2018/083698 patent/WO2019110691A1/en not_active Ceased
- 2018-12-05 AU AU2018379426A patent/AU2018379426B2/en active Active
- 2018-12-05 CA CA3083571A patent/CA3083571A1/en active Pending
- 2018-12-05 JP JP2020530462A patent/JP7744746B2/ja active Active
- 2018-12-05 EP EP18826197.8A patent/EP3720959A1/en active Pending
-
2023
- 2023-10-06 JP JP2023174103A patent/JP2024009895A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021509010A5 (enExample) | ||
| Utzschneider et al. | Early precursor T cells establish and propagate T cell exhaustion in chronic infection | |
| Ong et al. | A novel, five-marker alternative to CD16–CD14 gating to identify the three human monocyte subsets | |
| Yun et al. | Human plasmacytoid dendritic cells mount a distinct antiviral response to virus-infected cells | |
| Gordon et al. | Induction and maintenance of CX3CR1-intermediate peripheral memory CD8+ T cells by persistent viruses and vaccines | |
| Chu et al. | Continuous effector CD8+ T cell production in a controlled persistent infection is sustained by a proliferative intermediate population | |
| JP2018513212A5 (enExample) | ||
| Eggenhuizen et al. | Smith-specific regulatory T cells halt the progression of lupus nephritis | |
| Hartl et al. | Cis-regulatory landscapes of four cell types of the retina | |
| US9526749B2 (en) | Methods of isolating distinct pancreatic cell types | |
| JP2021500905A5 (enExample) | ||
| JP7608504B2 (ja) | 二重特異性および多重特異性生物学的物質の区画化されたアッセイ | |
| JP2016525366A5 (enExample) | ||
| Lagumdzic et al. | Transcriptome profiling of porcine naïve, intermediate and terminally differentiated CD8+ T cells | |
| Partanen et al. | Review of genetic variation as a predictive biomarker for chronic graft-versus-host-disease after allogeneic stem cell transplantation | |
| Kim et al. | A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained effector functions | |
| Hoerning et al. | Cyclosporin but not everolimus inhibits chemokine receptor expression on CD4+ T cell subsets circulating in the peripheral blood of renal transplant recipients | |
| Illing et al. | Kinetics of abacavir-induced remodelling of the major histocompatibility complex class I peptide repertoire | |
| Geng et al. | PICH Supports Embryonic Hematopoiesis by Suppressing a cGAS‐STING‐Mediated Interferon Response | |
| WO2020232148A1 (en) | Macrophage diversity in regenerative, fibrotic biomaterial environments | |
| Arner et al. | The contribution of bone marrow-derived cells to the human adipocyte pool | |
| JP2004527239A5 (enExample) | ||
| Lanna et al. | Kinetics of phenotypic and functional changes in mouse models of sponge implants: Rational selection to optimize protocols for specific biomolecules screening purposes | |
| WO2021144995A1 (ja) | 高純度間葉系幹細胞 | |
| Heikkilä et al. | Expanded CD4+ effector/memory T cell subset in APECED produces predominantly interferon gamma |